#Insilico Medicine #ISM9077 #ocular diseases

Insilico Medicine Introduces ISM9077: A Revolutionary AI-Driven Drug

In the rapidly evolving world of biotechnology, innovation is paramount, especially in the realm of drug discovery. Insilico Medicine, a leader in artificial intelligence (AI)-driven drug discovery, has made headlines with its latest nomination of ISM9077. This potential first-in-class Target Y inhibitor is being positioned as a preclinical candidate (PCC) aimed at addressing several serious health issues including ocular diseases, inflammatory disorders, and age-related conditions.

The Significance of ISM9077

ISM9077 stands out not only due to its dual-target approach towards treating ocular diseases, notably dry Age-Related Macular Degeneration (dry AMD), uveitis, and dry eye disease, but also for its promise in managing the broader implications of aging. As generative AI increasingly shapes the future of drug development, ISM9077 reflects the innovative edge of Insilico Medicine's methodologies. It is the 32nd PCC the company has nominated since 2021, showcasing the effectiveness of their AI-driven research.

Dr. Alex Zhavoronkov, Insilico's CEO, emphasized, “This candidate features not just a moderately novel target, but a brand-new molecule designed from the ground up. It's a testament to how generative AI facilitates drug development at scale.